ArticleBreast cancer (Tokyo, Japan)2022

Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.

Naruto Taira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.